Merck's Venture Arm Leads $7.3M Seed Round in Precision Chroma

Merck's corporate venture arm has led a $7.3 million seed round into Precision Chroma, a New Zealand biotechnology company, according to Dealroom.

The deal puts a major pharmaceutical investor at the table in one of the earliest stages of the company's life. Seed financing of this size, backed by a corporate venture arm rather than purely financial investors, signals that the strategic buyer saw something specific in the startup's technology.

Who is investing, and in what?

The lead investor is the venture arm of Merck, one of the world's largest pharmaceutical companies. The recipient is Precision Chroma, a biotech firm based in New Zealand. The round is a seed-stage financing totaling $7.3 million.

The company's name points toward chromatin or chromosome-related science, a field that has attracted growing corporate venture interest as big pharma hunts for novel drug discovery platforms. Dealroom's report, however, does not detail the specific technology pipeline or clinical programs the capital will fund.

Why does corporate venture money at seed stage matter?

Seed rounds are typically the domain of specialist early-stage funds and angel investors. When a pharmaceutical corporate venture arm leads at this stage, it often indicates the investor wants proximity to the technology before it matures — and before the price of entry rises.

For a New Zealand biotech, the deal carries extra weight. The country's biotech sector has historically struggled to attract large international checks at the earliest stages, and a $7.3 million seed round anchored by a global pharma investor stands out against that backdrop.

The structure also gives Precision Chroma more than cash. Corporate venture investors frequently open doors to internal expertise, development infrastructure and, eventually, commercial partnerships or acquisition conversations within the parent company's ecosystem.

What comes next?

The immediate question is deployment. Seed capital in biotech typically funds early validation work — platform proof-of-concept, initial assays and the hiring that turns a founder-led idea into a programmatic pipeline. Whether Precision Chroma can convert Merck's early conviction into a larger Series A will depend on the data that money produces.

The deal also adds a data point for investors watching where corporate venture dollars flow: early-stage, platform-adjacent biotech outside the traditional US and European hubs remains financable — when the strategic fit is right.